Back to products

LuciLorla 100 mg Tablet

Brand Name: LuciLorla

Molecule: Lorlatinib

Strength: 100 mg

Quantity: 30 Tablets

Form: Tablet

Packaging Type: Bottle

Manufacturer/Marketed By: Lucius Pharma

Country of Origin: Laos

Image	Product	Manufacturer / Marketed By	Price
	Lorbriqua 100 mg Tablet	Pfizer	Ask for Price
	Lorbrexen 100 mg Tablet	Everest Pharma	Ask for Price

Description

LuciLorla 100 mg Tablet is a prescription anti-cancer medicine containing Lorlatinib 100mg, a targeted therapy used in certain types of lung cancer. It belongs to a class of medicines known as tyrosine kinase inhibitors (TKIs), specifically designed to block abnormal proteins that help cancer cells grow and spread. This Lorlatinib tablet is commonly prescribed for patients diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) that tests positive for an abnormal gene called ALK (anaplastic lymphoma kinase). By targeting this genetic alteration, LuciLorla 100 mg Tablet plays an important role in modern, precision-based oncology care. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, Lorlatinib works in a more focused way. It is typically used when cancer has progressed despite earlier ALK inhibitor treatments or as directed by an oncologist

Benefits

Key clinically relevant benefits of LuciLorla 100 mg Tablet include:

Targets ALK gene alterations driving cancer growth
Designed for patients with resistant or progressive ALK-positive NSCLC
Demonstrated activity in metastatic disease, including brain metastases
Oral tablet formulation for convenient daily dosing
Precision-based therapy guided by molecular testing

These benefits are based on clinical research evaluating Lorlatinib in advanced ALK-positive lung cancer. Treatment outcomes vary depending on individual patient factors.

Indications and Usage

LuciLorla 100 mg Tablet (Lorlatinib 100mg) is indicated for:

Treatment of ALK-positive non-small cell lung cancer (NSCLC)
Patients with advanced or metastatic disease
Patients whose cancer has progressed after treatment with one or more prior ALK inhibitors
Situations where an oncologist determines Lorlatinib is clinically appropriate based on tumor genetics

Lorlatinib is specifically approved for ALK-positive lung cancer treatment, meaning it is effective only when cancer cells carry the ALK gene rearrangement. Testing for ALK mutation is required before starting therapy.

It is not used for all lung cancer types and should only be prescribed after proper diagnostic confirmation.

How it Works

Lorlatinib 100mg works by blocking a specific abnormal protein called ALK (anaplastic lymphoma kinase).

In some lung cancers, a genetic change causes the ALK protein to become overactive. This abnormal activity sends continuous growth signals to cancer cells, helping them multiply and survive.

LuciLorla 100 mg Tablet acts as an ALK tyrosine kinase inhibitor. It attaches to the altered ALK protein and blocks its signaling pathway. As a result:

Cancer cell growth slows down
Tumor progression may be controlled
Spread of cancer cells may be reduced

Because it targets a specific genetic mutation, Lorlatinib tablet is considered a form of targeted therapy rather than traditional chemotherapy.

Dosage & Administration

General dosing information (for reference only):
- Standard recommended dose: 100 mg orally, once daily.
- Can be taken with or without food.
- Tablets should be swallowed whole — do not crush, chew, or split.
- If a dose is missed, take it as soon as you remember — unless the next dose is within 4 hours. Never double up doses.
- Treatment continues until disease progression or unacceptable toxicity, as determined by your oncologist.
Important: Dosage adjustments may be required based on side effects, organ function, or drug interactions. Your oncologist will determine the right dosing regimen for your specific situation. Do not alter your dose without medical guidance.

Side Effects

Like all anti-cancer medicines, Lorlatinib 100mg may cause side effects. Not every patient experiences them, and their severity can vary.

Common Side Effects

Increased cholesterol or triglyceride levels
Swelling of hands, feet, or face
Weight gain
Fatigue
Mood changes or cognitive effects
Peripheral neuropathy (tingling or numbness in hands or feet)
Diarrhea or constipation

Serious Side Effects

Severe central nervous system (CNS) effects such as confusion or personality changes
Liver function abnormalities
Severe lipid elevation
Heart rhythm changes
Lung inflammation (rare but serious)

Patients should undergo regular blood tests to monitor liver function and cholesterol levels during treatment.

Contact your healthcare provider immediately if you experience severe or unusual symptoms.

Warning and Precaution

Before starting LuciLorla 100 mg Tablet, inform your doctor about your complete medical history.

Pregnancy and Breastfeeding

Lorlatinib may cause harm to an unborn baby.
Effective contraception is required during treatment and for a specified period after stopping therapy.
Breastfeeding is not recommended while taking this medicine.

Liver Function

Regular liver function monitoring is important, as Lorlatinib can affect liver enzymes.

Central Nervous System Effects

Some patients experience mood changes, memory issues, or speech difficulties. Inform your doctor if you notice any behavioral or neurological changes.

Cholesterol Elevation

Lorlatinib 100mg commonly increases cholesterol and triglyceride levels. Lipid levels should be checked before and during treatment.

Drug Interactions

Lorlatinib tablet may interact with:

Strong CYP3A inhibitors or inducers
Certain antifungal or antibiotic medicines
Herbal supplements like St. John’s Wort

Always inform your oncologist about all medications and supplements you are taking.

FAQ

What is LuciLorla 100 mg used for?+

LuciLorla 100 mg Tablet is used for the treatment of ALK-positive non-small cell lung cancer, particularly in advanced or metastatic cases.

Is Lorlatinib chemotherapy?+

No. Lorlatinib 100mg is a targeted therapy. It specifically blocks the ALK protein involved in cancer growth, unlike traditional chemotherapy that affects rapidly dividing cells broadly.

Can this Lorlatinib tablet be taken with food?+

It can generally be taken with or without food. However, follow your oncologist’s specific instructions.

How long does treatment last?+

Treatment duration depends on your response and tolerance. Your oncologist will determine how long you should continue therapy.

What should I do if I miss a dose?+

If you miss a dose, take it as soon as you remember unless it is close to the next scheduled dose. Do not take two doses at the same time. Always consult your doctor for guidance.

Does Lorlatinib work for all lung cancer patients?+

No. It is specifically indicated for ALK-positive lung cancer treatment. Genetic testing is required to confirm eligibility.

What are the 4 stages of lung cancer?

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 7, 2026.n n Lung cancer staging is

April 7, 2026

Sunvozertinib vs Chemo: A PFS Breakthrough in EGFR+ NSCLC

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 25, 2026.n n The treatment landscape for

March 25, 2026

Zongertinib Receives FDA Accelerated Approval for HER2+ NSCLC Treatment

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 28, 2026.n n The U.S. Food and

February 28, 2026

Rated 0 out of 5

0 reviews

Rated 5 out of 5

Rated 4 out of 5

Rated 3 out of 5

Rated 2 out of 5

Rated 1 out of 5

Reviews

Clear filters

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.